Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01380925 · ClinicalTrials.gov registry record

The Jewels in Our Genes Study - an African American Family Study of Breast Cancer

A clinical trial, sponsored by University at Buffalo.

Completed
Registry status
330
Enrollment target

NCT01380925: Completed study, sponsored by University at Buffalo.

NCT01380925 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 330 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01380925 has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
330 participants
Enrollment target

Study Summary

The research team is studying why some African American families have multiple cases of breast cancer. This study will help to better understand if there are undiscovered genes unique to African Americans that may predict early breast cancer risk. Breast cancer survivors AND their relatives who are also breast cancer survivors are being recruited to the study.

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2010-10
Est. Completion 2012-08
University at Buffalo

67 total trials

What the finished NCT01380925 record still lists

NCT01380925 is an observational study that tracks outcomes without assigning an intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01380925 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01380925 about?

NCT01380925 is a clinical study titled "The Jewels in Our Genes Study - an African American Family Study of Breast Cancer". The research team is studying why some African American families have multiple cases of breast cancer. This study will help to better understand if there are undiscovered genes unique to African Americans that may predict early breast cancer risk. Breast cancer survivors AND their relatives who ar...

What is the current status of trial NCT01380925?

This trial is currently completed. The enrollment target is 330 participants. The study started on 2010-10. Estimated completion is 2012-08.

Who is sponsoring clinical trial NCT01380925?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00359684 · 330 participants

    Use of Cysteamine in the Treatment of Cystinosis

  • NCT03817502 · 330 participants · Phase 3

    Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

  • NCT03922724 · 330 participants · Phase 2

    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

  • NCT03932773 · 330 participants · NA

    Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01380925, the US trial registry maintained by the National Library of Medicine. NCT01380925 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.